Web Results

caselaw.findlaw.com/us-supreme-court/09-152.html

Case opinion for US Supreme Court BRUESEWITZ ET AL. v. ... Respondent Wyeth purchased Lederle in 1994 and stopped manufacturing the vaccine in 1998. .... unavoidably unsafe product is defined by a hodge-podge of criteria and a few examples, such as the Pasteur rabies vaccine and experimental pharmaceuticals.

caselaw.findlaw.com/us-2nd-circuit/1533698.html

Aug 4, 2010 ... WYETH PHARMACEUTICALS, INC., Walter Wardrop, Andrew Schaschl, and Michael McDermott, Defendant-Appellees. ... Law § 290, et seq. Henry contends that the district court erred in granting two of defendants' motions in limine; by improperly instructing the jury as to his burden of proof; and by failing ...

healthland.time.com/2011/02/24/bruesewitz-v-wyeth-what-the-supreme-court-decision-means-for-vaccines

Feb 24, 2011 ... Congress created these “Vaccine Courts” with the participation of pharmaceutical companies as a sort of “societal bargain” — as Justice Antonin Scalia noted in the majority decision in Bruesewitz v. Wyeth — to ensure the future of vaccine availability in the U.S. At the time of the Act, hundreds of injury ...

www.law.cornell.edu/supct/cert/09-152

Bruesewitz v. Wyeth, Inc. (09-152). Oral Argument: Oct. 12, 2010. Appealed From: United States Court of Appeals for the Third Circuit (Mar. 8, 2010) ... right of vaccine victims to seek compensation for their injuries and the ability of vaccine manufacturers to avoid costly litigation that may drive them out of the vaccine market.

www.oyez.org/cases/2010/09-152

Oct 12, 2010 ... Bruesewitz v. Wyeth Inc. ... Respondent. Wyeth, Inc., fka Wyeth Laboratories, et al . ... The majority reasoned that Congress had set up a special vaccine court as a way to provide compensation to injured children without driving drug manufacturers from the vaccine market. Justice Stephen Breyer filed a ...

respectfulinsolence.com/2011/02/23/the-supreme-court-rules-on-bruesewitz-v

Feb 23, 2011 ... Several large jury awards convinced pharmaceutical companies that the risk of producing vaccines was just too high relative to the potential profit. Due to the fear that litigation might well drive vaccine manufacturers either out of business or leave them no choice but to stop up manufacturing vaccines due to ...

search.rpxcorp.com/litigation_documents/12279350

Dec 23, 2016 ... Wyeth LLC, Wyeth Pharmaceuticals Inc. (“Wyeth Inc.”) and PF PRISM C.V., ... business at 1 Commerce Drive, Cranbury, New Jersey 08512. .... Pharma AG et al. v. Alembic Pharms. Ltd. et al., No. 1:15-cv-00832-GMS (D. Del.) (D.I. 12). ( Alembic Pharmaceuticals, Ltd. and Alembic Pharmaceuticals, Inc.

howappealing.abovethelaw.com/SimonVsWyethReplyBriefForAppellantFinal.pdf

v. WYETH PHARMACEUTICALS, INC., et al.,. Defendants. No. 2620 EDA 2007: Appeal of plaintiff Merle Simon;. No. 2673 EDA 2007: Cross–appeal of defendant Pharmacia & Upjohn Co., LLC. REPLY BRIEF FOR APPELLANT/. RESPONSE BRIEF FOR CROSS–APPELLEE. On Appeal from the Judgment of the Court of ...

www.canr.msu.edu/iflr/uploads/files/Student%20Papers/Fyan.FDL%20final.pdf

Dec 8, 2006 ... (2003). 2 MG Rosenthal, et al., Promotion of Prescription Drugs to Consumers, 346 N Engl J. Med. 498 (2002). 2002. ... in Perez v. Wyeth Laboratories, Inc. 4 The court's analysis in this case highlights the increased liability risk for pharmaceutical companies in continuing to advertise directly to consumers.